GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

Although both GLP-1 and GLP-2 are substrates for DPP-4 with similar Km values, DPP-4's kcat for GLP-1 is 7.1 s −1 as opposed to 0.87 s −1 for GLP-2; thus, the former is degraded nine times ...

Thus, to evaluate the potential of GLP-1 as a new agent for the treatment of type 2 diabetes, it is important to investigate the effect of combination therapy with GLP-1 and other antidiabetic agents.

DPP-4 inhibitors and GLP-1 analogues are widely used to treat people with type 2 diabetes. People with moderately elevated blood glucose are said to be at an increased risk for developing type 2 ...

A preclinical animal study showed that the combination of dorzagliatin and sitagliptin, a DPP-4 inhibitor, improves blood glucose levels, promotes insulin secretion, and enhances GLP-1 secretion.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023.

The Saudi Arabia diabetes market reached a value of USD 373.4 million in 2024 and is projected to grow to USD 494.4 million by 2033, exhibiting a steady compound annual growth rate (CAGR) of 3.17% ...

A recent study found that more than half of patients with overweight or obesity (53.6%) discontinued GLP-1 therapy within one year (53.6%), a number that grows to 72.2% by two years.

Indian pharma speeds up access to global therapies while targeting treatment gaps: Nandita Vijayasimha, Bengaluru Saturday, June 28, 2025, 08:00 Hrs [IST] Indian pharma is now agg ...

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for ...

The combination therapy, especially the triplet regimen, is associated with a higher incidence of side effects compared to semaglutide alone. Notable side effects include: Gastrointestinal Issues: ...